(Q34562770)

3 August 2017

1 reference

title

Pharmacogenetics and the concept of individualized medicine (English)

1 reference

3 August 2017

Shastry BS

1

1 reference

PubMed ID

16302022

3 August 2017

language of work or name

1 reference

1 January 2006

1 reference

The Pharmacogenomics Journal

3 August 2017

1 reference

3 August 2017

6

1 reference

3 August 2017

16-21

1 reference

3 August 2017

1

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.tpj.6500338

3 August 2017

0 references

cites work

Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Readmissions and adverse drug reactions in internal medicine: the economic impact.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Sequencing drug response with HapMap

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

How molecular profiling could revolutionize drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Measuring the value of pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Drug metabolism and variability among patients in drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Genetic diversity and new therapeutic concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Pharmacogenetics goes genomic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Clinical pharmacogenetics of immunosuppressive drugs in organ transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Molecular basis of ethnic differences in drug disposition and response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Methotrexate-induced pancytopenia: serious and under-reported? Our experience of 25 cases in 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Human thiopurine S-methyltransferase pharmacogenetics: variant allozyme misfolding and aggresome formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Epidemiology of hypersensitivity drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Tumor necrosis factor alpha polymorphism in heart failure/cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Pharmacogenetics in heart failure: genomic markers of endothelial and neurohumoral function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Pharmacogenomics of blood pressure response to antihypertensive treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Human response to alpha2-adrenergic agonist stimulation studied in an isolated vascular bed in vivo: Biphasic influence of dose, age, gender, and receptor genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

The emerging pharmacogenomics of the beta-adrenergic receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Molecular properties and pharmacogenetics of a polymorphism of adenylyl cyclase type 9 in asthma: interaction between beta-agonist and corticosteroid pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Beta(2)-adrenergic receptor polymorphisms and response to salbutamol among Indian asthmatics*.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Pharmacogenetics in the treatment of depression: pharmacodynamic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Pharmacogenetics as a tool in the therapy of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

The relationship between the pharmacology of antiepileptic drugs and human gene variation: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

The role of common variation in drug transporter genes in refractory epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

New ideas on the origin of L-dopa-induced dyskinesias: age, genes and neural plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Genetics and variability in opioid response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Advances in opioid pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Melanocortin-1 receptor gene variants affect pain and mu-opioid analgesia in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: I. Identification of polymorphisms in the 5'-regulatory and exon 1 regions, and association with human liver UGT1A6 gene expression and glucuronidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Lack of association between single nucleotide polymorphisms in the corticotropin releasing hormone receptor 1 (CRHR1) gene and alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Pharmacogenetics and geographical ancestry: implications for drug development and global health

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Pharmacogenetics and ethnically targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Ethnic differences in allele frequency of autoimmune-disease-associated SNPs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

On the probability that a novel variant is a disease-causing mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Use of race and ethnicity in biomedical publication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Systematic investigation of genetic variability in 111 human genes-implications for studying variable drug response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Warfarin: a case history in pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Factors determining the maintenance dose of warfarin in Chinese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Heparin therapy in the Chinese--lower doses are required.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Combination of isosorbide dinitrate and hydralazine in blacks with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Priorities and standards in pharmacogenetic research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

Pharmacogenetics for individualized cancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

A review on the design and reporting of studies on drug-gene interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

7 January 2021

Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

7 January 2021

A multilocus approach to the antihypertensive pharmacogenetics of hydrochlorothiazide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

7 January 2021

[Pharmacogenetics in future medical care -- implications for patients and physicians]

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500338

7 January 2021

Identifiers

DOI

10.1038/SJ.TPJ.6500338

1 reference

PubMed ID

16302022

Dimensions Publication ID

3 August 2017

0 references

1 reference

PubMed ID

16302022